Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 413

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Phase 2b Controlled Trial of M72/AS01 E Vaccine to Prevent Tuberculosis

Open access
Van Der Meeren, Olivier, Hatherill, Mark, Nduba, Videlis, Wilkinson, Robert J., Muyoyeta, Monde, Van Brakel, Elana, Ayles, Helen M., Henostroza, German, Thienemann, Friedrich, Scriba, Thomas J., Diacon, Andreas, Blatner, Gretta L., Demoitié, Marie-Ange, Tameris, Michele, Malahleha, Mookho, Innes, James C., Hellström, Elizabeth, Martinson, Neil, Singh, Tina, Akite, Elaine J., Khatoon Azam, Aisha, Bollaerts, Anne, Ginsberg, Ann M., Evans, Thomas G., Gillard, Paul, Tait, Dereck R. · 2018 · New England Journal of Medicine

Abstract

BACKGROUNDA vaccine to interrupt the transmission of tuberculosis is needed. METHODSWe conducted a randomized, double-blind, placebo-controlled, phase 2b trial of the M72/AS01 E tuberculosis vaccine in Kenya, South Africa, and Zambia.Human immunodeficiency virus (HIV)-negative adults 18 to 50 years of age with latent M. tuberculosis infection (by interferon-γ release assay) were randomly assigned (in a 1:1 ratio) to receive two doses of either M72/AS01 E or placebo intramuscularly 1 month apart.Most participants had previously received the bacille Calmette-Guérin vaccine.We assessed the safety of M72/AS01 E and its efficacy against progression to bacteriologically confirmed active pulmonary tuberculosis disease.Clinical suspicion of tuberculosis was confirmed with sputum by means of a polymerase-chain-reaction test, mycobacterial culture, or both. RESULTSWe report the primary analysis (conducted after a mean of 2.3 years of follow-up) of the ongoing trial.A total of 1786 participants received M72/AS01 E and 1787 received placebo, and 1623 and 1660 participants in the respective groups were included in the according-to-protocol efficacy cohort.A total of 10 participants in the M72/AS01 E group met the primary case definition (bacteriologically confirmed active pulmonary tuberculosis, with confirmation before treatment), as compared with 22 participants in the placebo group (incidence, 0.3 cases vs. 0.6 cases per 100 person-years).The vaccine efficacy was 54.0% (90% confidence interval [CI], 13.9 to 75.4; 95% CI, 2.9 to 78.2; P = 0.04).Results for the total vaccinated efficacy cohort were similar (vaccine efficacy, 57.0%; 90% CI, 19.9 to 76.9; 95% CI, 9.7 to 79.5; P = 0.03).There were more unsolicited reports of adverse events in the M72/ AS01 E group (67.4%) than in the placebo group (45.4%) within 30 days after injection, with the difference attributed mainly to injection-site reactions and influenzalike symptoms.Serious adverse events, potential immune-mediated diseases, and deaths occurred with similar frequencies in the two groups. CONCLUSIONSM72/AS01 E provided 54.0% protection for M. tuberculosis-infected adults against active pulmonary tuberculosis disease, without evident safety concerns.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1803484

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 413

Metadata

Authors
Van Der Meeren, O., Hatherill, M., Nduba, V., Wilkinson, R. J., Muyoyeta, M., Van Brakel, E., Ayles, H. M., Henostroza, G., Thienemann, F., Scriba, T. J., Diacon, A., Blatner, G. L., Demoitié, M.-A., Tameris, M., Malahleha, M., Innes, J. C., Hellström, E., Martinson, N., Singh, T., Akite, E. J., Khatoon Azam, A., Bollaerts, A., Ginsberg, A. M., Evans, T. G., Gillard, P., & Tait, D. R.
Venue
New England Journal of Medicine
Published
2018-10-25
Volume
379
Issue
17
Pages
1621-1634
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2894391687
Cited by
413
References
31
FWCI
39.08
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 2b Controlled Trial of M72/AS01 E Vaccine to Prevent Tuberculosis. https://app.cochat.ai/papers/10.1056/nejmoa1803484
The paper
Van Der Meeren, O., Hatherill, M., Nduba, V., Wilkinson, R. J., Muyoyeta, M., Van Brakel, E., Ayles, H. M., Henostroza, G., Thienemann, F., Scriba, T. J., Diacon, A., Blatner, G. L., Demoitié, M.-A., Tameris, M., Malahleha, M., Innes, J. C., Hellström, E., Martinson, N., Singh, T., . . . Tait, D. R. (2018). Phase 2b Controlled Trial of M72/AS01 E Vaccine to Prevent Tuberculosis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1803484

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.